Thank you Ali Taher for presenting our latest #Thalassemia clinical trial data, ENERGIZE: A Global Phase 3 Study of Mitapivat Demonstrating Efficacy and Safety in Adults with Alpha- or Beta-Non-Transfusion-Dependent Thalassemia, at #EHA2024. See the data here:

It is with great honor to announce that I have been inducted to Sigma Xi, The Scientific Research Honor Society, as a full member "in recognition of my scholarly achievements and contributions to the advancement of knowledge in my field of study".

Meaningful productivity is about making a life that matters. For me, a life that matters centers on people that matter Faculty of Medicine American University of Beirut Medical Center #Collaboration #Mentorship

An institution that resembles none… yet serves all. American University of Beirut Medical Center

Through its primary health care center, the Department of Family Medicine, quickly responded to the Ministry of Public Health's call to provide health services to internally displaced individuals in collective shelters. #AUBFM #AUB #AUBMC #MoPH #Lebanon #AUBMedicine

In an interview from #ASCAT2024, Ali Taher of American University of Beirut Medical Center provides an update on the ENERGIZE trial of mitapivat in NTD alpha- and beta-thalassemia. Click here to watch: 👉 ow.ly/TRkw50THLqp 👈 #Thalassemia #Hematology #CTSM #TrialUpdate Academy for Sickle Cell & Thalassaemia (ASCAT)

“Strong leadership in crises ensures universities & hospitals stay resilient, adapt quickly, and continue serving their communities. Decisive choices safeguard education & healthcare while fostering unity. #Leadership #CrisisManagement American University of Beirut”

Together, we can make hope grow even in the hardest of times. Since its inception in 2018, the Cancer Support Fund has helped thousands of patients, but to continue this vital mission, we need your support. Let’s come together for cancer patients in need. Donate today and

Pleased to share my updated 2025 AD SCI index ranking first in Hematology in Lebanon, third in Asia, and 60th globally. Citations are the reason we do it, to inform the research journey of others, towards advancing global knowledge of diseases and their treatments

Excited to share our last publication. In this paper, we explored how Mitapivat is playing a promising role for the treatment of various hemolytic disorders, offering new hope for patients!✨ Ali Taher Mohammad Hassan Hodroj 🙏🏽 pubmed.ncbi.nlm.nih.gov/39880584/

Discover More About Us and how HPDC is dedicated to advancing healthcare professional development! Join us as Dr. Ali Taher, our Associate Vice President for Academic Centers, Development and External Affairs, unveils our mission and impact! American University of Beirut Medical Center Ali Taher Faculty of Medicine

Pleased to share our ‘mini’ version and editorial on the new TIF Guidelines for the Managamement of Transfusion-Dependent beta-Thalassaemia out today in HemaSphere Journal (IF = 14.6) Ali Taher onlinelibrary.wiley.com/doi/full/10.10…

A landmark global phase 3 clinical trial led by Dr. Ali Taher from AUB and the Chronic Care Center marks a breakthrough in thalassemia care. Published in The Lancet, the study is the first to demonstrate the efficacy of an oral therapy—mitapivat—for both alpha and beta forms of

A landmark global trial led by AUB’s Dr. Ali Taher and the Chronic Care Center marks a major breakthrough in thalassaemia care. Published in The Lancet, the study is the first to show an effective oral therapy for both alpha and beta forms of non–transfusion-dependent